AstraZeneca’s shares fell over 5% following disappointing results from its TROPION-Lung01 Phase III trial, which showed its experimental lung cancer drug did not improve survival rates.
AstraZeneca lung cancer drug
Breaking News
AstraZeneca’s shares fell over 5% following disappointing results from its TROPION-Lung01 Phase III trial, which showed its experimental lung cancer drug did not improve survival rates.
